Two Phase 3 Trials of Datopotamab Deruxtecan Plus Durvalumab Initiated in Patients Across Two Breast Cancer Subtypes

TROPION-Breast04 is evaluating Daiichi Sankyo and AstraZeneca’s datopotamab deruxtecan plus durvalumab as neoadjuvant treatment for early-stage triple negative and HR low, HER2 low or negative breast cancers TROPION-Breast05 is evaluating...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials